

Original Article

Comparison of ticagrelor with clopidogrel in Chinese ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention

Rui Jing, Wenhua Lin

Department Cardiology ONE, TEDA International Cardiovascular Hospital, Tianjin 300457, China

Received May 10, 2016; Accepted July 26, 2016; Epub December 15, 2016; Published December 30, 2016

Abstract: Background: Ticagrelor has shown better efficacy and safety in comparison with clopidogrel in acute coronary syndrome patients. However, there is a paucity of evidence supporting the use of ticagrelor in Chinese ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Materials and methods: This is a prospective, randomized, parallel design, investigator initiated, pharmacodynamic study carried out at our hospital from June 2014 to May 2015. Patients were randomized in a 1:1 ratio to receive a loading dose (LD) of clopidogrel 600 mg and aspirin 300 mg (n = 94) or ticagrelor 180 mg and aspirin 300 mg (n = 94). The adenosine diphosphate (ADP) inhibition rate and the maximum amplitude were measured using the thrombelastography at various time points post LD. Results: The ADP inhibition rates at 0.5 h, 1 h, 2 h, and 4 h were significantly higher for ticagrelor in comparison with clopidogrel ($P < 0.05$). The maximum amplitude at 0.5 h, 1 h, 2 h, and 4 h were significantly lower for ticagrelor in comparison with clopidogrel ($P < 0.05$). Conclusion: Ticagrelor is more potent with faster onset in comparison with clopidogrel in Chinese STEMI patients treated with primary PCI.

Keywords: Acute myocardial infarction, percutaneous coronary intervention, ticagrelor, clopidogrel


Introduction

The advances in the treatments of ST-segment elevation myocardial infarction (STEMI) have significantly decreased the mortality of patients with acute MI [1]. Thrombosis in the coronary artery is one of the most important causes of acute MI. Platelets play a crucial role in the development of thrombosis. Atherosclerotic plaque rupture damages the vascular endothelium and platelets adhere to the matrix beneath the damaged endothelium. The platelet aggregation leads to the thrombosis and blocks the vessel. The platelet activation can be inhibited by targeting the synthesis of thromboxane A₂, the adenosine diphosphate (ADP) signaling pathway, and the glycoprotein IIb/IIIa signaling pathway [2]. The most commonly used antiplatelet agents include aspirin, clopidogrel, and tirofiban. Conclusive evidences show that antiplatelet therapy can significantly decrease the mortality and risk of cardiovascular events in

MI patients. For acute MI patients treated with primary PCI, dual antiplatelet therapy post procedure is an important method for the prevention of stent thrombosis and in-stent restenosis. The CURE study and the CREDO trial established the treatment basis using aspirin and clopidogrel as post-PCI medications [3, 4]. However, despite the use of dual antiplatelet therapy, cardiovascular events still occur in approximately 20% of acute MI patients, such as subacute thrombosis and sudden death [5-7].

Interindividual variability in the responsiveness to antiplatelet agents have well been documented. The low platelet reactivity to clopidogrel is of great clinical interest in the treatment of coronary diseases and has been intensively investigated. Ticagrelor is a third-generation P2Y₁₂ inhibitor with faster onset and higher potency [8-10]. In comparison with clopidogrel, ticagrelor does not require the metabolite oxi-

Ticagrelor and clopidogrel in myocardial infarction



evidences supporting the efficacy and safety of ticagrelor in Chinese STEMI patients.

The present study was designed to investigate the platelet inhibition ability of ticagrelor in comparison with clopidogrel in Chinese STEMI patients treated with primary PCI.

Materials and methods

Patients

This is a prospective, randomized, parallel design, investigator initiated, pharmacodynamic study carried out at our hospital from June 2014 to May 2015. Patients were included if they presented with STEMI within 12 h and planned to receive primary PCI. Patients with the following conditions were excluded from this study: contraindications to clopidogrel or ticagrelor; had thrombolysis within 24 h; was on glycoprotein IIb/IIIa inhibitors prior to the PCI; was already on oral anticoagulants and needed to continue the medications after the procedure; severe bradycardia or conduction block; severe liver or kidney impairment; active bleeding or coagulation disorder; age > 75 years.

Study protocol

The finally included patients were randomized in a 1:1 ratio to receive a loading dose (LD) of clopidogrel 600 mg and aspirin 300 mg (n = 94) or ticagrelor 180 mg and aspirin 300 mg (n = 94). After the primary PCI, a maintenance dose of clopidogrel 75 mg daily or ticagrelor 90 mg daily was used for each group for at least 12 months, respectively. Aspirin 100 mg daily was used indefinitely. Peripheral blood was collected from each patient at 0.5 h, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h, 48 h, and 72 h after the LD. The ADP inhibition rate and the maximum amplitude were measured using the thrombelastography (Hemostasis Analyzer Model 5000, Haemoscope, IL, USA). A flow chat diagram of the study is shown in **Figure 1**.

The study protocol was approved by the Ethics Committee of TEDA International Cardiovascular Hospital. Informed consent was obtained from each patient before the enrollment.

Table 1. Patients' demographic and clinical characteristics

	Clopidogrel 600 mg (n = 94)	Ticagrelor 180 mg (n = 94)	P
Male (n)	58	54	0.94
Age (year)	55±16	59±21	0.99
Diabetes (n)	23	26	0.99
Smoking (n)	36	33	0.88
BMI (kg/m ²)	25.13±2.61	24.08±4.14	0.61
Hypertension	51	56	0.83
Dyslipidemia	42	36	0.54
Prior MI	14	10	0.66
Prior PCI	18	22	0.70

BMI, Body mass index; MI, Myocardial infarction; PCI, Percutaneous coronary intervention.

Table 2. Adenosine diphosphate inhibition rate (%) in patients treated with clopidogrel or ticagrelor

	Clopidogrel 600 mg (n = 94)	Ticagrelor 180 mg (n = 94)	P
0.5 h	8.3±1.2	41.1±10.1	0.008
1 h	21.0±4.1	70.2±20.1	0.013
2 h	38.4±10.2	88.6±19.9	0.047
4 h	51.7±9.8	86.1±24.4	0.032
6 h	62.1±11.4	87.2±20.8	0.097
12 h	66.5±20.4	80.4±30.4	0.184
24 h	73.4±19.3	82.0±27.5	0.331
48 h	72.0±27.2	84.7±20.8	1.13
72 h	74.3±15.3	81.9±17.9	1.102

ductive activation in the liver and is associated with lower platelet reactivity. Many clinical studies have shown that ticagrelor is superior to clopidogrel with better efficacy and lower rate of clinical events. However, there is a paucity of




Figure 2. Adenosine diphosphate (ADP) inhibition rate and maximum amplitude in patients treated with clopidogrel or ticagrelor. *, $P < 0.05$.

Table 3. Maximum amplitude in patients treated with clopidogrel or ticagrelor

	Clopidogrel 600 mg (n = 94)	Ticagrelor 180 mg (n = 94)	P
0.5 h	64.4±20.2	59.5±16.6	0.009
1 h	55.7±18.4	45.4±9.8	0.042
2 h	56.8±19.7	43.7±14.7	0.037
4 h	52.7±14.8	36.5±9.9	0.031
6 h	46.1±13.5	39.8±10.2	0.182
12 h	40.4±9.7	37.5±10.5	0.213
24 h	42.8±11.8	40.2±11.1	0.446
48 h	38.4±17.5	35.8±14.4	0.089
72 h	44.4±20.2	41.5±19.8	1.021

Statistical analysis

Continuous data were presented as mean ± standard deviation and categorical data were presented as frequencies. Comparisons were made using the independent t-test for the continuous data and using the Fisher’s exact test for the categorical data. All statistical analyses were performed using the SPSS 19.0 software (SPSS, Chicago, IL, USA). $P < 0.05$ was considered statistically significant.

Results

A total of 221 patients were considered for inclusion in this study and 33 were excluded (Figure 1). Demographic and clinical characteristics of the randomized patients are shown in Table 1. No significant differences were noticed

the demographic and clinic information between the two groups.

The thrombelastography showed that the ADP inhibition rates at 0.5 h, 1 h, 2 h, and 4 h were significantly higher for ticagrelor in comparison with clopidogrel ($P < 0.05$). There was a non-significant trend toward higher ADP inhibition rates at 6 h, 12 h, 24 h, 48 h, and 72 h for ticagrelor in comparison with clopidogrel (Table 2; Figure 2).

The maximum amplitude at 0.5 h, 1 h, 2 h, and 4 h were significantly lower for ticagrelor in comparison with clopidogrel ($P < 0.05$). There was a non-significant trend toward lower maximum amplitude at 6 h, 12 h, 24 h, 48 h, and 72 h for ticagrelor compared with clopidogrel (Table 3; Figure 2).

There were two case of in-hospital death due to cardiac rupture, one in the clopidogrel and another one in the ticagrelor group. Mild bleeding occurred in 17 patients treated with clopidogrel, including gingival bleeding in 6 patients, skin bruise in 7 patients, nosebleed in 1 patient, and hemorrhoidal bleeding in 3 patients. Mild bleeding occurred in 23 patients treated with ticagrelor, including gingival bleeding in 4 patients, skin bruise in 15 patients, conjunctival bleeding in 2 patients, nosebleed in 1 patient, and hemorrhoidal bleeding in 1 patient. There was no significantly difference in the rate of mild bleeding between the two groups ($P = 0.37$). No life-threatening bleeding

or intracranial hemorrhage was documented in either group.

Discussion

Our study found that ticagrelor 180 mg is associated with significantly higher ADP inhibition rate and significantly lower maximum amplitude in comparison with clopidogrel 600 mg in the first 4 hours after the loading dose in STEMI patients treated with primary PCI.

Ticagrelor inhibits the P2Y₁₂ receptor in a reversible manner and does not require the oxidative activation in the liver. The platelet inhibition of ticagrelor is more potent and faster in comparison with other antiplatelet agents [11, 12]. The PLATO trial compared the efficacy and safety of ticagrelor in comparison with clopidogrel in 18,624 acute coronary syndrome (ACS) patients recruited from 862 centers of 43 countries [13]. This study found that ticagrelor significantly reduced the risk of the composite endpoint of cardiovascular death, MI, and stroke in comparison with clopidogrel without increasing the overall bleeding rate in ACS patients. The RESPOND study showed that ticagrelor is effective in both clopidogrel responders and nonresponders [14].

Although ticagrelor has shown better efficacy and safety in comparison with clopidogrel, these evidences are obtained from patients with stable coronary artery disease or broad ACS. There is a paucity of data of ticagrelor in STEMI patients. In addition, STEMI patients often need dual or triple antiplatelet agents or heparin-based anticoagulation therapy, which is associated increased risk of bleeding. The safety of ticagrelor in the STEMI patients should be further evaluated. The difference in antiplatelet agent efficacy between different regions and races is also a concern [15]. However, the use of ticagrelor in Chinese STEMI patients is still not adequately supported. Our study compared the platelet inhibition rate and the maximum amplitude of ticagrelor with clopidogrel in Chinese STEMI patients treated with primary PCI using the thrombelastography. Thrombelastography is a well-established method for measuring platelet inhibition. In thrombelastography, an ADP inhibition rate > 70% and a maximum amplitude < 47 suggest satisfactory platelet inhibition. Our results showed that ticagrelor is more potent with fas-

ter onset in comparison with clopidogrel in STEMI patients treated with primary PCI. Ticagrelor onset was 1 h after the LD, while clopidogrel onset was 6 h after the LD. It took 24 h that clopidogrel reached the same inhibition rate of platelets as ticagrelor. Therefore, the advantages of higher potent and faster onset of ticagrelor also exist in Chinese patients.

In conclusion, ticagrelor is more potent with faster onset in comparison with clopidogrel in Chinese STEMI patients treated with primary PCI.

Disclosure of conflict of interest

None.

Abbreviations

STEMI, ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; LD, loading dose; ADP, adenosine diphosphate; ACS, acute coronary syndrome; BMI, body mass index.

Address correspondence to: Dr. Wenhua Lin, Cardiology Department ONE, TEDA International Cardiovascular Hospital No. 61, 3rd Street, Tianjin Economic-Technological Development Area (TEDA), Tianjin 300457, China. Tel: +86-13602117922; Fax: +86-22-65209052; E-mail: linwernhua@sina.com

References

- [1] Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, Flather MD, Budaj A, Quill A and Gore JM. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. *JAMA* 2007; 297: 1892-1900.
- [2] Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. *Nat Rev Drug Discov* 2010; 9: 154-169.
- [3] Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney EM, Bouin O, Gabriel S, Jackson J, Chen R, Caro J, Steinhubl S, Topol E and Weintraub WS. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. *J Am Coll Cardiol* 2005; 46: 761-769.
- [4] Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I

Ticagrelor and clopidogrel in myocardial infarction

- and Fox KA. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001; 358: 527-533.
- [5] Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D and Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. *Circulation* 2013; 127: e6-e245.
- [6] Singh M, Williams BA, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, Cutlip DE and Holmes DR Jr. Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial. *J Am Coll Cardiol* 2006; 47: 34-39.
- [7] Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK and Tantry US. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. *J Am Coll Cardiol* 2005; 46: 1820-1826.
- [8] Joshi RR, Hossain R, Morton AC, Ecob R, Judge HM, Wales C, Walker JV, Karunakaran A and Storey RF. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes. *Platelets* 2014; 25: 416-422.
- [9] Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS and Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. *Circulation* 2009; 120: 2577-2585.
- [10] Husted S and van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. *Cardiovasc Ther* 2009; 27: 259-274.
- [11] Nylander S, Femia EA, Scavone M, Berntsson P, Asztély AK, Nelander K, Löfgren L, Nilsson RG and Cattaneo M. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. *J Thromb Haemost* 2013; 11: 1867-1876.
- [12] VAN GIEZEN JJ, NILSSON L, BERNTSSON P, WISSING BM, GIORDANETTO F, TOMLINSON W and GREASLEY PJ. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. *J Thromb Haemost* 2009; 7: 1556-1565.
- [13] Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009; 361: 1045-1057.
- [14] Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV and Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. *Circulation* 2010; 121: 1188-1199.
- [15] Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA and Wallentin L. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. *Circulation* 2011; 124: 544-554.